News

Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss
Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...
Ultragenyx Pharmaceutical Inc.: Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled Phase ...
Santé log22h
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...
BP Flags Up to $1.5 Billion Impairment While Earnings Are Hit by Weaker Prices — Update
The British energy major said Friday that it anticipates booking $500 million to $1.5 billion in after-tax impairment charges alongside its second-quarter earnings. These charges are considered ...
BP flags lower gas, oil price hit for second quarter
BP's second-quarter results will be hit by lower prices it received for its gas and oil, it said in a quarterly trading ...
BP’s Upstream Chief Lays Out the Mechanics of Turnaround Plan
BP Plc has put an oil and gas revival at the heart of its turnaround plan, and upstream chief Gordon Birrell is leading the ...
The World's First $4 Trillion Company
Nvidia reaches $4T market cap, solidifying its dominance in the AI revolution. Discover insights, stock analysis, and more in ...
BPM Partners' Latest Performance Management Vendor Landscape Matrix Adds New Details, New Vendors, And Agentic AI Coverage
Edition Adds AI-generated Customer Feedback Summaries and Platform GraphicsSTAMFORD, Conn., July 10, 2025 (GLOBE NEWSWIRE) -- BP ...